Clik here to view.
Qurient Announces U.S. FDA Clearance of IND Application for Q901, a Novel...
SEONGNAM-SI, South Korea Qurient Co. Ltd. (KRX: 115180), a clinical stage biotech company, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug...
View ArticleClik here to view.
武田制药取得强劲的2021财年第三季度业绩，调高全年预测，以反映强劲发展势头
日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda, TOKYO:4502/NYSE:TAK)今天公布了强劲的2021财年第三季度业绩（截至2021年12月31日的期间），这一业绩得益于其14个全球品牌稳健的营收增长。基于强劲的第三季度业绩和业务势头，武田更新了整个财年营收、列报经营利润和核心经营利润、列报每股收益和核心每股收益以及自由现金流的预测。...
View ArticleClik here to view.
EdiGene and Neukio Enter Collaboration to Develop Next-Generation Immune Cell...
BEIJING & SHANGHAI & CAMBRIDGE, Mass. EdiGene, Inc., a global biotechnology company focused on translating gene-editing technologies into transformative therapies for patients with serious...
View ArticleClik here to view.
Alvotech与BiosanaPharma达成全球独家许可协议，共同开发Xolair®（奥马珠单抗）的拟议生物仿制药(AVT23)
冰岛雷克雅未克和荷兰莱顿 (美国商业资讯)–完全专注于为全球患者开发和生产生物仿制药的全球性生物制药公司Alvotech Holdings S.A. (“Alvotech”)已经与BiosanaPharma达成了一项全球独家许可协议，共同开发Xolair®（奥马珠单抗）的拟议生物仿制药AVT23（也称BP001）。 本新闻稿包含多媒体。此处查看新闻稿全文：...
View ArticleClik here to view.
AKSO and Huadong Medicine Announce Strategic Collaboration to Develop and...
LOS ANGELES & LONDON & HANGZHOU, China AKSO Biopharmaceutical, Inc. (“AKSO”), a global biopharmaceutical company with an innovative and comprehensive approach to treat cancer, autoimmune...
View ArticleClik here to view.
Clik here to view.
Orum Therapeutics to Participate in February Investor Conferences
BOSTON & DAEJEON, South Korea Orum Therapeutics, a biotechnology company pioneering the development of tumor-directed targeted protein degraders, today announced that the Company’s leadership...
View ArticleClik here to view.
EdiGene Announces Publication by Company Scientific Founder in Nature...
BEIJING & CAMBRIDGE, Mass. EdiGene, Inc., a global biotechnology company, today announced its Scientific Founder Wensheng Wei’s lab at Peking University has published a research article in...
View ArticleClik here to view.
雷迪博士实验室达成收购德国医用大麻公司Nimbus Health GmbH的最终协议
德国法兰克福和印度海德拉巴 (美国商业资讯)–雷迪博士实验室有限公司（Dr. Reddy’s Laboratories Ltd., BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY，连同其子公司一起称为“雷迪博士”）今天宣布已达成一项收购Nimbus Health GmbH（简称“Nimbus Health”）的最终协议。Nimbus...
View ArticleClik here to view.
Mandy Moore与Lumenis合作，提高对干眼症和OptiLight疗法的认识
以色列约克尼姆伊利特 (美国商业资讯)–Lumenis今天宣布已与唱作人兼演员Mandy Moore合作，由Mandy Moore担任干眼症理想解决方案OptiLight的品牌大使。Moore女士患有干眼症，OptiLight疗法使她的病情得到明显改善。现在她与Lumenis合作，分享她的故事，并激励其他人。她将出演OptiLight的新广告，告诉数以百万计的干眼症患者，不必“默默忍受”。...
View ArticleClik here to view.
Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154...
SAN DIEGO Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease...
View ArticleClik here to view.
Vaxxas Announces Appointment of Scott Fry Ph.D. as Chief Operating Officer
CAMBRIDGE, Mass. & BRISBANE, Australia Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, is pleased to announce a key appointment to its executive...
View ArticleClik here to view.
Modalis Therapeutics to Present Data Supporting of Development of...
TOKYO & WALTHAM, Mass. Modalis Therapeutics Corporation (Tokyo Stock Exchange: 4883), a pioneering company developing innovative products for the treatment of rare genetic diseases utilizing its...
View ArticleClik here to view.
Takeda Presents New Exploratory Analysis Showing Patients Treated With...
OSAKA, Japan & CAMBRIDGE, Mass. Takeda (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it will present four company-sponsored abstracts at the Tandem Transplantation & Cellular Therapy...
View ArticleClik here to view.
Turnstone Biologics Announces TIL Therapy Research Collaboration with the...
NEW YORK Turnstone Biologics Corp., a clinical-stage biotechnology company developing next-generation tumor-infiltrating lymphocyte (“TIL”) therapy and viral immunotherapy designed to treat and cure...
View ArticleClik here to view.
Arrowhead Pharmaceuticals and Vivo Capital Launch Joint Venture Aimed at...
PASADENA, Calif. Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has formed a joint venture, Visirna Therapeutics, with Vivo Capital to expand the reach of innovative medicines...
View ArticleClik here to view.
Dalrada Health’s cerVIA™ Test Kit Enables Immediate Results with Second...
SAN DIEGO Dalrada Corporation (OTCQB: DFCO, “Dalrada”), an innovator in healthcare, green energy, and technology, today announced that the Company completed a second clinical trial on its...
View ArticleClik here to view.
Porton Advanced and Sinorda Biomedicine Enter Strategic Collaboration to...
SUZHOU, China Suzhou Porton Advanced Solutions Ltd. (‘Porton Advanced’) and Guizhou Sinorda Biomedicine Co. Ltd (‘Sinorda Biomedicine’) today announced a long-term strategic partnership in cell and...
View ArticleClik here to view.
RPIDD 传染病液体活检技术脱氧核糖核酸 文库制备和扩增方法获首项专利
纽约、伦敦和巴黎 (美国商业资讯)–临床阶段的生物制药公司知临集团有限公司（纳斯达克代码：APM，巴黎泛欧证券交易所代码：APM）（「知临集团」或「知临」）欣然宣布，美国专利商标局已授予A* STAR机构有关快速病原体传染病液体活检诊断（「RPIDD」）的专利 (美国专利号码: US11,280,028 B1)。A* STAR机构是一家总部位于新加坡的机构，知临通过其子公司 Aptorum...
View ArticleClik here to view.
First Patent Regarding RPIDD Infectious Disease Liquid Biopsy Technology DNA...
NEW YORK & LONDON & PARIS Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, is pleased to...
View Article